Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...

Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...

Shares of Incyte Corp. INCY slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

UBS lowered the firm’s price target on Incyte (INCY) to $61 from $69 and keeps a Neutral rating on the shares. The stock has held up since the ...

Each RSU vests as to 25% of the shares subject to the RSU on each of the first four anniversaries of the vesting commencement date, subject to the employee's continued service with the Company on each ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...